Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203775 | 0.89 | ALDH1A1 (0.60) | GAAALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL4719920 | 0.88 | ALDH1A1 (0.52) | GAAALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL6492363 | 0.88 | PTGDR2 (0.55) | GAAALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL276196 | 0.88 | NTRK1 (0.57) | ALDH1A1HPGDL3MBTL1MAPTRAB9A | |
| SCHEMBL1968834 | 0.85 | TRPM8 (0.60) | GAAALDH1A1HPGDMAPTTRPM8 | |
| SCHEMBL8791044 | 0.84 | RORC (0.43) | GAAALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL1398786 | 0.82 | GAA (0.57) | GAAALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL19626518 | 0.81 | KDM4E (0.53) | MAPTRAB9ANPC1KDM4E | |
| SCHEMBL12922064 | 0.80 | TRPM8 (0.53) | GAAALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4786383 | 0.77 | DHODH (0.62) | GAAALDH1A1HPGDL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641342-B | Thiazolidine derivatives as orexin receptor antagonist | ACTELION PHARMACEUTICAL LTD CH | 2012-10-03 | — | — | CN | disclosed |
| US-8236964-B2 | Thiazolidine derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-07 | — | — | US | disclosed |
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100113531-A1 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-06 | — | — | US | disclosed |
| CN-101641342-A | Thiazolidine derivatives | ACTELION PHARMACEUTICAL LTD CH | 2010-02-03 | — | — | CN | disclosed |
| EP-2125760-A2 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101506199-A | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-12 | — | — | CN | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008117241-A2 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113531-A1 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | GAA 3348/4885ALDH1A1 680/4885HPGD 2304/4885 |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | GAA 2145/4885ALDH1A1 1961/4885HPGD 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.